87828-86-2
87828-86-2
Chemical Structure
L-Leucine-d3
- CAS No.: 87828-86-2
- Formula:C6H10D3NO2
- Molecular Weight:134.19
IUPAC Name: L-leucine-5,5,5-d3
InChIKey: ROHFNLRQFUQHCH-LONBSJBQSA-N
SMILES: [2H]C([2H])([2H])C(C)C[C@H](N)C(O)=O
Biological Activity: L-Leucine-d3 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway[1].
| Cat. No. | 상품명 | Purity | 제품 설명 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
L-Leucine-d3 | 99.98% | L-Leucine-d3 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine (Standard) | 99.94% | L-Leucine (Standard) is the analytical standard of L-Leucine. This product is intended for research and analytical applications. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-d | L-Leucine-d is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-2-13C,15N | 98.0% | L-Leucine-2-13C,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-13C6 | 99.92% | Leucine-13C6 is the 13C-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-d7 | 99.7% | L-Leucine-d7 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-d10 | 99.0% | L-Leucine-d10 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-d2 | 99.81% | L-Leucine-d2 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-18O2 | 98% | L-Leucine-18O2 is the 18O-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-13C | 99.90% | L-Leucine-13C is the 13C-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-15N,d10 | L-Leucine-15N,d10 is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-2-13C | 98% | L-Leucine-2-13C is the 13C-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-13C6,15N | 99.90% | L-Leucine-13C6,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-15N | 99.84% | L-Leucine-15N is the 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine-1-13C,15N | 99.93% | L-Leucine-1-13C,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Leucine | 98.0% | L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Valine-d7 | L-Valine-d7 is the deuterium labeled L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Alanine-d3 | 99.83% | D-Alanine-d3 is the deuterium labeled D-Alanine. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-2-Aminohexanoic acid-d9 | D-2-Aminohexanoic acid-d9 is the deuterium labeled D-2-Aminohexanoic acid. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Leucine | 99.95% | (±)-Leucine (DL-Leucine), an isomer of Leucine, chemosterilant and dietary additive. (±)-Leucine inhibits growth of Escherichia coli HfrH by 92.08%. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Leucine-d10 | 98.0% | (±)-Leucine-d10 is the deuterium labeled (±)-Leucine. (±)-Leucine (DL-Leucine), an isomer of Leucine, chemosterilant and dietary additive. (±)-Leucine inhibits growth of Escherichia coli HfrH by 92.08%. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Leucine-d7 | 99.89% | (±)-Leucine-d7 is the deuterium labeled (±)-Leucine. (±)-Leucine (DL-Leucine), an isomer of Leucine, chemosterilant and dietary additive. (±)-Leucine inhibits growth of Escherichia coli HfrH by 92.08%. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Alloisoleucine-d10 | L-Alloisoleucine-d10 is the deuterium labeled L-Alloisoleucine. L-Alloisoleucine is a branched chain amino acid and is a stereo-isomer of L-isoleucine. L-Alloisoleucine is a common constituent of human plasma (albeit at low levels). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Valine-d8 | 99.91% | L-Valine-d8 is a deuterated form of L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Alanine-d3 | 99.92% | L-Alanine-d3 is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Valine-d8 | 99.09% | D-Valine-d8 is the deuterium labeled D-Valine. D-Valine is the enantiomer of L-Valine (HY-N0717). L-Valine is one of 20 proteinogenic amino acids. L-Valine is an essential amino acid. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Valine-13C5,15N,d8 | L-Valine-13C5,15N,d8 ((S)-Valine-13C5,15N,d8) is the deuterium, 13C-, and 15N-labeled L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Isoleucine-d10 | 98.6% | DL-Isoleucine-d10 is the deuterium labeled L-Isoleucine. L-isoleucine is a nonpolar hydrophobic amino acid. L-Isoleucine is an essential amino acid. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Isoleucine-d10 | 99.89% | L-Isoleucine-d10 is the deuterium labeled L-Isoleucine. L-isoleucine is a nonpolar hydrophobic amino acid. L-Isoleucine is an essential amino acid. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Isoleucine-13C6,15N,d10 | 99.9% | L-Isoleucine-13C6,15N,d10 is the deuterium, 13C-, and 15-labeled L-Isoleucine. L-isoleucine is a nonpolar hydrophobic amino acid. L-Isoleucine is an essential amino acid. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Alanine-d3 | 98.0% | DL-Alanine-d3 is the deuterium labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-2-Aminobutyric acid-d3 | L-2-Aminobutyric acid-d3 is the deuterium labeled L-2-Aminobutyric acid. L-2-Aminobutyric acid is a non-proteinogenic amino acid that exists in human tissues and body fluids. L-2-Aminobutyric acid is formed by the transamination of oxobutyric acid. L-2-Aminobutyric acid can serve as a precursor for anticonvulsant and anti-tuberculosis agents and is a key intermediate in the chemical and pharmaceutical industries. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Rac)-2-Aminobutyric acid-d3 | (Rac)-2-Aminobutyric acid-d3 is the deuterium labeled (Rac)-2-Aminobutyric acid. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-2-Aminohexanoic acid-d9 | DL-2-Aminohexanoic acid-d9 is the deuterium labeled DL-2-Aminohexanoic acid. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Valine-d8 | 99.96% | DL-Valine-d8 is the deuterium labeled DL-Valine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Isovaleric acid-d7 | 99.47% | Isovaleric acid-d7 is the deuterium labeled Isovaleric acid. Isovaleric acid is a natural fatty acid and known to effect on neonatal death and possible Jamaican vomiting sickness in human. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
α-Ketoisocaproic acid-d7 | α-Ketoisocaproic acid-d7 is the deuterium labeled α-Ketoisocaproic acid. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-3-Amino-2-methylpropanoic acid-d3 | (R)-3-Amino-2-methylpropanoic acid-d3 is the deuterium labeled (R)-3-Amino-2-methylpropanoic acid. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Homoleucine | L-Homoleucine (H-HoLeu-OH) (Compound 10) is a non-proteinogenic amino acid building block. L-Homoleucinemycoplanecin is present in Mycoplanecin. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-Aminobutanoic-4,4,4 acid hydrochloride-d3 | 2-Aminobutanoic-4,4,4 acid hydrochloride-d3 is the deuterium labeled 2-Aminobutanoic-4,4,4 acid hydrochloride. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Formyl-L-leucine-d3 | N-Formyl-L-leucine-d3 (N-Formyl-S-leucine-d3) is deuterium labeled N-Formyl-L-leucine. N-Formyl-L-leucine is a leucine derivative. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S)-Leucic acid-d3 | (S)-Leucic acid-d3 ((S)-2-Hydroxy-4-methylpentanoic acid-d3) is the deuterated-labeled (S)-Leucic acid (HY-30215). (S)-Leucic acid ((S)-2-Hydroxy-4-methylpentanoic acid) is an α-hydroxy acid found in the fermentation products of Bacillus granulobacter pectinovorum. (S)-Leucic acid is an isomer of Leucic acid (HY-30216A) and a leucine metabolite. (S)-Leucic acid acts as a D-unit subunit precursor in the biosynthesis of cryptophycins in the Nostoc cyanobacterial symbiont. (S)-Leucic acid is used in metabolism-related studies. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Norleucine-d9 | 99.81% | L-Norleucine-d9 is the deuterium labeled L-Norleucine. L-Norleucine ((S)-2-Aminohexanoic acid) is an isomer of leucine, specifically affects protein synthesis in skeletal muscle, and has antivirus activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Leucine | 98.0% | D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Leucine (Standard) | 99.87% | D-Leucine (Standard) is the analytical standard of D-Leucine. This product is intended for research and analytical applications. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Leucine-d10 | 99.96% | D-Leucine-d10 is the deuterium labeled D-Leucine. D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Norvaline-d5 | 99.9% | L-Norvaline-d5 is the deuterium labeled L-Norvaline. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
